Session Item

Modalities of use of androgen deprivation therapy may depend on tumor aggressiveness, patient frailty and physician habits. Our purpose here was to describe main reasons of planned total duration of triptorelin treatment declared by the physician in real life, according to circumstance of prescription.

Initiated in November 2020, a prospective, multicenter, non-interventional study is ongoing in France (TALISMAN, NCT04593420). Urologists, radiation oncologists and medical oncologists recruited patients with histologically confirmed prostate cancer (PCa), eligible for a ≥ 12-month triptorelin therapy within its label. Decision of initiation of triptorelin treatment was made before inclusion. 786 patients were planned to be enrolled, with a 12-month follow-up. Primary objective is to describe the proportion of patients treated continuously with triptorelin for 12 months after initiation. Interim analysis of baseline data was planned when 50% of patients were enrolled. A descriptive analysis of baseline parameters of subgroups according to circumstance of prescription [high risk localized tumor (HRL), locally advanced tumor (LA), biochemical recurrence (BCR), metastatic stage (MS)] was performed.

509 patients were included in the interim analysis. Main circumstances of prescription were HRL (38.8%) and MS (28.1%). Main baseline parameters by circumstance of prescription are presented in Table (except for ‘other circumstance’, 21 patients (4.5%)). Gleason score ≥ 4+3 was particularly frequent in HRL (77.2%) and MS (78.8%) subgroups.

Main reasons of choice of planned total duration of triptorelin treatment differed between subgroups of circumstances of prescription. First reason was adapted to PCa stage: Gleason score for high risk PCa (49.4% in HRL and 32.4% in LA), PSA level (28.6%) for BCR, number of bone metastases (35.5%) for MS. Tumor aggressiveness seems to be the main driver of choice, with parameter adapted to the stage.